CClinicalTrials.gg
TerminatedNCT05112640Updated Aug 21, 2024Results posted

Subcuticular Absorbable Staples Versus Conventional Skin Closure in Women Undergoing Cesarean Delivery

An interventional study of INSORB: subcuticular stapling device and Subcuticular monocryl suture manufactured by Ethicon in Operative Time and Wound Heal, sponsored by The University of Texas Medical Branch, Galveston. Terminated at 1 site in United States. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by The University of Texas Medical Branch, Galveston · Not applicable, Interventional, and Other

Why this study was terminated
low accrual
Phase
Not applicable
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Despite the high numbers of cesareans being performed, scientific evidence behind which surgical techniques are best remains uncertain. Our objective is to determine if subcuticular absorbable staples improve operative time and wound cosmetics.

Read the detailed description

This will be an open-label randomized controlled clinical trial. Women undergoing cesarean delivery will be randomized to have either standard wound closure with Monocryl suture or absorbable subcuticular staples placed by INSORB skin stapling device. The INSORB under the skin stapling device is FDA approved but not currently used as standard of care at UTMB. We will exclude women with intraamniotic infection, immunosuppression, active skin infection, those unlikely to be followed-up after delivery, or unable to provide consent.

02

Conditions studied

  • Operative Time
  • Wound Heal
03

In context

Lead sponsor

The University of Texas Medical Branch, Galveston is the lead sponsor of 251 studies on the registry; 38 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • 18-50 years of age
  • Women ≥ 24 weeks viable gestation
  • Will be undergoing cesarean delivery

Exclusion criteria

Exclusion Criteria:

  • Patient unwilling or unable to provide consent.
  • No or very limited prenatal care or a non-resident patient who is unlikely to follow-up after delivery.
  • Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g. transplant subjects; not including steroids for lung maturity), HIV with CD4 \<200, or other
  • Decision not to have skin closure (e.g. secondary wound closure, mesh closure)
  • Current skin infection
  • Coagulopathy
  • High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled hysterectomy, tubal ligation, bowel or adnexal surgery)
  • Incarcerated individuals
  • Intraamniotic infection
  • Subjects participating on other treatment trials or studies that would interfere with the current study's primary outcome.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
117 participants (actual)

Study arms

  • Active comparator
    Suture wound closure

    Absorbable sutures for closure of cesarean skin incision using Monocryl manufactured by Ethicon.

    Device: Subcuticular monocryl suture manufactured by Ethicon

  • Experimental
    Absorbable staple wound closure

    Staples will be applied as per the manufacturer's instructions intraoperatively using INSORB device manufactured by Cooper Surgical.

    Device: INSORB: subcuticular stapling device

Interventions

  • DeviceINSORB: subcuticular stapling device

    Under the skin stapling device that delivers absorbable staples

  • DeviceSubcuticular monocryl suture manufactured by Ethicon

    Under the skin suture placed by hand

06

What researchers measure

Primary outcomes

  1. Operating Time

    Total time for the procedure

    Time frame: Start of surgery through end of skin closure in minutes

Secondary outcomes

  1. Wound Cosmesis

    A digital photograph of the incision will be obtained on wound check visit POD 5-10 days. Each photograph will be evaluated by independent blinded research staff using the Stony Brook Scar Evaluation Scale.These scores are totaled to obtain the final score. The Stony Brook Scar Evaluation will score the scar from 0-5 where 5 shows significant healing.

    Time frame: Time of surgery through six weeks post partum

  2. Number of Participants With Composite Wound Complication

    Hematoma, seroma, dehiscence, breakdown of wound, wound infection, endometritis, sepsis, post part fevers

    Time frame: Time of surgery through six weeks post partum

  3. Post Operative Pain

    Analog pain scale ranging from 0-10. This is a standard question that nurses as during the post partum period while in the hospital and clinic/nursing visits. The numerical score will be recorded from the patient's chart. A score of 0 means no pain, and 10 means the worst pain.

    Time frame: 5-10 days

  4. Number of Adverse Events

    Allergic reactions: anaphylaxis, angioedema, skin rashes, including Stevens Johnson and Toxic Epidermal Necrolysis

    Time frame: Time of surgery through six weeks post partum

  5. Use of Resources

    Postpartum clinic or emergency room visit within 30 days of delivery, need for imaging or other invasive procedures

    Time frame: Time of surgery through six weeks post partum

  6. Skin Closure Time in Minutes

    The average of minutes it takes for closure of the skin at time of surgery through weeks post partum.

    Time frame: Time of surgery through six weeks post partum

07

Results

Posted Aug 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneSuture Wound ClosureAbsorbable Staple Wound Closure
Started5956
Completed5956
Not completed00

Outcome measures

PrimaryOperating Time

Total time for the procedure

Time frame:
Start of surgery through end of skin closure in minutes
Reported as:
Mean · Minutes
Operating Time
MinutesSuture Wound ClosureAbsorbable Staple Wound Closure
Operating Time69.2 ± 23.761.9 ± 21.2
SecondaryWound Cosmesis

A digital photograph of the incision will be obtained on wound check visit POD 5-10 days. Each photograph will be evaluated by independent blinded research staff using the Stony Brook Scar Evaluation Scale.These scores are totaled to obtain the final score. The Stony Brook Scar Evaluation will score the scar from 0-5 where 5 shows significant healing.

Time frame:
Time of surgery through six weeks post partum
Reported as:
Mean · score on a scale
Wound Cosmesis
score on a scaleSuture Wound ClosureAbsorbable Staple Wound Closure
Wound Cosmesis3.9 ± 1.03.2 ± 1.2
SecondaryNumber of Participants With Composite Wound Complication

Hematoma, seroma, dehiscence, breakdown of wound, wound infection, endometritis, sepsis, post part fevers

Time frame:
Time of surgery through six weeks post partum
Reported as:
Count of participants · Participants
Number of Participants With Composite Wound Complication
ParticipantsSuture Wound ClosureAbsorbable Staple Wound Closure
Number of Participants With Composite Wound Complication02
SecondaryPost Operative Pain

Analog pain scale ranging from 0-10. This is a standard question that nurses as during the post partum period while in the hospital and clinic/nursing visits. The numerical score will be recorded from the patient's chart. A score of 0 means no pain, and 10 means the worst pain.

Time frame:
5-10 days
Reported as:
Mean · Units on a scale
Post Operative Pain
Units on a scaleSuture Wound ClosureAbsorbable Staple Wound Closure
Post Operative Pain.9 ± 2.2.7 ± 1.9
SecondaryNumber of Adverse Events

Allergic reactions: anaphylaxis, angioedema, skin rashes, including Stevens Johnson and Toxic Epidermal Necrolysis

Time frame:
Time of surgery through six weeks post partum
Reported as:
Count of participants · Participants
Number of Adverse Events
ParticipantsSuture Wound ClosureAbsorbable Staple Wound Closure
Number of Adverse Events00
SecondaryUse of Resources

Postpartum clinic or emergency room visit within 30 days of delivery, need for imaging or other invasive procedures

Time frame:
Time of surgery through six weeks post partum
Reported as:
Count of participants · Participants
Use of Resources
ParticipantsSuture Wound ClosureAbsorbable Staple Wound Closure
Use of Resources01
SecondarySkin Closure Time in Minutes

The average of minutes it takes for closure of the skin at time of surgery through weeks post partum.

Time frame:
Time of surgery through six weeks post partum
Reported as:
Mean · minutes
Skin Closure Time in Minutes
minutesSuture Wound ClosureAbsorbable Staple Wound Closure
Skin Closure Time in Minutes7.6 ± 2.74.1 ± 2.67

Adverse events

Collected over baseline until the end of the study, up to 6 weeks postpartum. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Suture Wound Closure0/59 (0%)0/59 (0%)0/59 (0%)
Absorbable Staple Wound Closure0/56 (0%)0/56 (0%)0/56 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Suture Wound ClosureAbsorbable Staple Wound ClosureTotal
Mean29.5 ± 531.1 ± 5.230.3 ± 5.2
Sex: Female, Male
Sex: Female, Male(Participants)Suture Wound ClosureAbsorbable Staple Wound ClosureTotal
Female5956115
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Suture Wound ClosureAbsorbable Staple Wound ClosureTotal
Hispanic or Latino434083
Not Hispanic or Latino161632
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Suture Wound ClosureAbsorbable Staple Wound ClosureTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American9817
White504898
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Suture Wound ClosureAbsorbable Staple Wound ClosureTotal
United States5956115
08

Study locations

1 site
  • John Sealy Hospital at University of Texas Medical Branch
    Galveston, Texas 77555, United States
09

References and documents

Publications

  • Frishman GN, Schwartz T, Hogan JW. Closure of Pfannenstiel skin incisions. Staples vs. subcuticular suture. J Reprod Med. 1997 Oct;42(10):627-30. PubMed 9350017 ↗
  • Gaertner I, Burkhardt T, Beinder E. Scar appearance of different skin and subcutaneous tissue closure techniques in caesarean section: a randomized study. Eur J Obstet Gynecol Reprod Biol. 2008 May;138(1):29-33. doi: 10.1016/j.ejogrb.2007.07.003. Epub 2007 Sep 6. PubMed 17825472 ↗
  • Rousseau JA, Girard K, Turcot-Lemay L, Thomas N. A randomized study comparing skin closure in cesarean sections: staples vs subcuticular sutures. Am J Obstet Gynecol. 2009 Mar;200(3):265.e1-4. doi: 10.1016/j.ajog.2009.01.019. PubMed 19254586 ↗
  • Fick JL, Novo RE, Kirchhof N. Comparison of gross and histologic tissue responses of skin incisions closed by use of absorbable subcuticular staples, cutaneous metal staples, and polyglactin 910 suture in pigs. Am J Vet Res. 2005 Nov;66(11):1975-84. doi: 10.2460/ajvr.2005.66.1975. PubMed 16334959 ↗
  • Pineros-Fernandez A, Salopek LS, Rodeheaver PF, Drake DB, Edlich RF, Rodeheaver GT. A revolutionary advance in skin closure compared to current methods. J Long Term Eff Med Implants. 2006;16(1):19-27. doi: 10.1615/jlongtermeffmedimplants.v16.i1.30. PubMed 16566742 ↗
  • Nitsche J, Howell C, Howell T. Skin closure with subcuticular absorbable staples after cesarean section is associated with decreased analgesic use. Arch Gynecol Obstet. 2012 Apr;285(4):979-83. doi: 10.1007/s00404-011-2121-5. Epub 2011 Oct 30. PubMed 22037686 ↗
  • Schrufer-Poland TL, Ruiz MP, Kassar S, Tomassian C, Algren SD, Yeast JD. Incidence of wound complications in cesarean deliveries following closure with absorbable subcuticular staples versus conventional skin closure techniques. Eur J Obstet Gynecol Reprod Biol. 2016 Nov;206:53-56. doi: 10.1016/j.ejogrb.2016.07.501. Epub 2016 Aug 3. PubMed 27632411 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 30, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — Do not plan to share IPD.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05112640
Lead sponsor
The University of Texas Medical Branch, Galveston
Collaborators
Cooper Companies
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Nov 16, 2021
Primary completion
Dec 31, 2023
Completion
Mar 31, 2024
Results posted
Aug 21, 2024
Last update
Aug 21, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion